# Selvedge Venture

Selvedge Venture is a Venture Capital based in London, United Kingdom.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** London, United Kingdom
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** www.selvedgeventure.com
- **LinkedIn:** https://www.linkedin.com/company/selvedge-venture

## Regulatory record

- **Reports private funds:** No

## About

RISK WARNING: Don’t invest unless you’re prepared to lose all the money you invest. This is a high‑risk investment and you are unlikely to be protected if something goes wrong. NOT FOR RETAIL CLIENTS – The information contained on this website is solely intended for professional investors, defined as investors who (1) qualify as professional […]

## Sectors

- Digital Health
- Healthcare Services
- AI/ML
- Biotech
- Neuroscience
- Metabolic Health
- Oncology

## People

- Alasdair Thong — Founder
- Robert Thong — Founder

## Questions

### Who runs investment decisions at Selvedge Venture?

Founders Alasdair Thong and Robert Thong run the firm. The website lists them as the two principals; titles beyond 'Founder' are not published, and no separate CIO or investment committee is disclosed.

### What is the firm's investment focus?

Selvedge Venture invests exclusively into companies targeting the three age-related medical conditions that account for the largest share of global healthcare spend and mortality: metabolic syndrome (including cardiovascular disease, diabetes, fatty liver disease, and obesity), cancer, and neurodegenerative diseases. Every position must sit at the confluence of biotechnology and digital/machine-learning tooling.

### What stages does Selvedge Venture target?

The firm invests from Pre-Seed through Series A, with a commitment to founders and start-ups whose science is ready for scaling. No later-stage or growth-equity activity is mentioned in its public materials.

### Can you name specific portfolio companies?

Publicly referenced positions span cell therapy manufacturing (Kytopen, which raised a $30 million Series A), glucose-responsive insulin technology via Carbometrics' collaboration with Novo Nordisk and the University of Bristol (published in Nature), AI-driven clinical triage, transdermal drug delivery, computational systems biology, and a chemistry platform. The firm groups its companies under descriptors rather than publishing a full portfolio list.

### Does Selvedge Venture participate in fund commitments or only direct deals?

Public disclosures describe only direct early-stage equity investments into operating companies. No fund-of-funds activity, SPV structures, or co-investment clubs are mentioned on the firm's website or in available public records.

### What is the firm's geographic mandate?

Selvedge Venture is headquartered in London. Its portfolio extends to innovation clusters in the United Kingdom and Cambridge, Massachusetts, the latter linked to a cell therapy manufacturing spinout from an MIT lab. No additional office locations are listed.

## Related profiles

- [Selva Ventures](https://altss.com/profile/selva-ventures)
- [Sema Investment](https://altss.com/profile/sema-investment)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/selvedge-venture

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology